A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Clinical trial NCT05291234 · COMPLETED

Trial details

NCT number: NCT05291234
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer's Disease (AD)

Start date: 2022-08-15
Primary completion: 2025-11-19
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.